The AHA 2013 Scientific Sessions "is the leading cardiovascular meeting for basic, translational, clinical and population science, in the United States," and is designed to "improve patient care by communicating the most timely and significant advances in prevention, diagnosis and treatment of cardiovascular disease from many different perspectives."
Ticagrelor Prescribed Less Frequently than other Antiplatelet Agents Overall, but Used More Often in Higher-Risk Patients
Effect of Proton Pump Inhibitor Use on Risk of CV Events in Patients Treated with Rivaroxaban and a Thienopyridine
Vorapaxar Associated with Reductions in Cardiovascular Death, MI, and other Negative Outcomes in Patient with Peripheral Artery Disease
Patients with non-ST-segment elevation (non-STEMI) acute coronary syndrome and peripheral artery disease (PAD) treated with the PAR-1 antagonist vorapaxar experienced a reduction in ischemic events and other outcomes compared to patients who received placebo, with no increased risk of bleeding compared to patients who did not have PAD.
Although oral antiplatelet therapy is broadly supported as preventive therapy for patients with established atherosclerotic vascular disease, researchers say emerging evidence for specific agents shows heterogeneous outcomes by symptomatic vascular bed, and patterns of use may vary by symptomatic territory.
Study of the Antiplatelet Effects of Ticagrelor vs. Clopidogrel in Hispanic Patients with Stable Coronary Artery Disease
Comparison of the Utility of a Validated Questionnaire with Daily Electronic Diary Entry in Patients with Chronic Angina
Cardiac Arrest Often Preceded by Specific Warning Signs; Researchers Looking for Ways to Improve Risk Assessment
Researchers with the Oregon Sudden Unexpected Death Study are working to understand the mechanisms of sudden cardiac arrest by "searching for novel determinants of this condition that will facilitate the identification of subjects at risk, with the overall goal of improving prevention of sudden cardiac arrest" and improving the current low rate of successful resuscitation.
Cardiac Resynchronization Therapy (CRT) a Plus for Atrial Fibrillation Patients: Results from the CERTIFY Study